Development and validation of a stability-indicating HPLC assay method for simultaneous determination of spironolactone and furosemide in tablet formulation.
The objective of the current study was to develop and validate a simple, precise and accurate isocratic stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) assay method for the determination of spironolactone and furosemide in solid pharmaceutical dosage forms. Isocratic RP-HPLC separation was achieved on an SGE 150 × 4.6 mm SS Wakosil II 5C8RS 5-μm column using a mobile phase of acetonitrile-ammonium acetate buffer (50:50, v/v) at a flow rate of 1.0 mL/min. The detection was carried out at 254 nm using a photodiode array detector. The drug was subject to oxidation, hydrolysis, photolysis and heat to apply stress conditions. The method was validated for specificity, linearity, precision, accuracy, robustness and solution stability. The method was found to be linear in the drug concentration range of 40-160 µg/mL with correlation coefficients of 0.9977 and 0.9953 for spironolactone and furosemide, respectively. The precision (relative standard deviation; RSD) among a six-sample preparation was 0.87% and 1.1% for spironolactone and furosemide, respectively. Repeatability and intermediate precision (RSD) among a six-sample preparation were 0.46% and 0.20% for spironolactone and furosemide, respectively. The accuracy (recovery) was between 98.05 and 100.17% and 99.07 and 100.58% for spironolactone and furosemide, respectively. Degradation products produced as a result of stress studies did not interfere with the detection of spironolactone and furosemide; therefore, the assay can be considered to be stability-indicating.
Department of Chemistry, Krantiguru Shyamji Krishna Verma Kachchh University, Bhuj-370 001, Gujarat, India.
Vijay R
VR
Ram
Pragnesh N
PN
Dave
Hitendra S
HS
Joshi
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D005665:Furosemide / Q000032:analysis* / Q000737:chemistry; D016014:Linear Models; D015203:Reproducibility of Results; D013148:Spironolactone / Q000032:analysis* / Q000737:chemistry; D013607:Tablets / Q000737:chemistry
D013607:Tablets; D013148:Spironolactone; D005665:Furosemide